Systemic sclerosis & Raynaud's
CRTAC1: a novel indicator of lung involvement in SSc
Authors' conclusion
Systemic levels of CRTAC1 are decreased in SSc patients, especially among those with ILD, reduced lung function and elevated disease activity.
Study context
- Population
- SSc patients (2013 ACR/EULAR criteria) and healthy individuals; plasma CRTAC1 measured by IQ-ELISA
- Participants
- 76 vs 89
- Exposure
- SSc patients vs healthy controls; SSc with interstitial lung disease (ILD) vs SSc without ILD
- SScn = 76
- HCn = 89reference
- Outcome
- Plasma CRTAC1 levels
Main finding
As reported in the abstract
- SSc vs HC: P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| CRTAC1 in SSc with vs without ILDDecreased with ILD | P = 0.027 |
Linear modelling: association of CRTAC1 with clinical measures
- Disease Severity Scale (DSS) pulmonary involvement (negative), β
- −2.46; P = 0.016
- European Scleroderma Study Group (ESSG) activity score (negative), β
- −2.022; P = 0.047
- DLCO (positive), β
- 1.87; P = 0.065
- FEV1 (positive), β
- 1.622; P = 0.1
- Forced vital capacity (FVC) (positive), β
- 1.83; P = 0.072
CRTAC1 by other organ involvement (decreased with involvement)
- Gastrointestinal involvement
- P = 0.002
- Joint involvement
- P = 0.006
- PAH
- P = 0.05
Original publication
CRTAC1: a novel indicator of lung involvement in SSc. Rheumatology (Oxford). Published 23 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →